Welcome to our dedicated page for INOVIO PHARMACEUTICALS SEC filings (Ticker: INO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on INOVIO PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into INOVIO PHARMACEUTICALS's regulatory disclosures and financial reporting.
INOVIO Pharmaceuticals is a clinical-stage biotech focused on DNA medicines delivered with its proprietary CELLECTRA electroporation devices to treat HPV-associated diseases, cancer and infectious diseases. The company has no approved products and generates only collaboration and licensing revenue.
Its lead candidate, INO‑3107 for recurrent respiratory papillomatosis, has a Biologics License Application under FDA review with a standard 10‑month timeline and a PDUFA target date of October 30, 2026. The FDA has questioned whether current data support use of the accelerated approval pathway. INOVIO reports strong Phase 1/2 data showing durable reductions in surgery frequency.
The pipeline also includes INO‑3112 for HPV‑positive throat cancer, INO‑5401/INO‑5412 for glioblastoma and BRCA‑related cancers, and multiple infectious disease programs and DNA‑encoded antibody and protein platforms. Management discloses that INOVIO does not have sufficient working capital to fund planned operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern and underscoring reliance on new capital.
Humeau Laurent reported acquisition or exercise transactions in this Form 4 filing.
INOVIO PHARMACEUTICALS, INC. Chief Scientific Officer Laurent Humeau reported equity awards on common stock on March 4, 2026. He received a grant of 26,840 stock options vesting in three annual installments on February 26 of 2027, 2028 and 2029. He also received 21,560 restricted stock units, which vest in similar annual tranches from February 26, 2027 through February 26, 2029 and represent contingent rights to receive common shares, cash or a combination of both upon vesting.
INOVIO PHARMACEUTICALS, INC. Chief Executive Officer Jacqueline Elizabeth Shea reported equity awards consisting of stock options and restricted stock units. On March 4, 2026, she acquired 97,240 stock options and 78,760 restricted stock units as grants, each at a price of $0.00 per unit.
According to the vesting schedule, 32,414 of the options vest on February 26, 2027, 32,413 on February 26, 2028, and 32,413 on February 26, 2029. For the 78,760 restricted stock units, 26,254 vest on February 26, 2027, 26,253 on February 26, 2028, and 26,253 on February 26, 2029, with each unit representing a right to one share of common stock, settleable in stock, cash, or a combination.
Sumner Michael John reported acquisition or exercise transactions in this Form 4 filing.
INOVIO PHARMACEUTICALS, INC. reported that Chief Medical Officer Michael John Sumner received new equity awards. On March 4, 2026, he was granted options to purchase 36,832 shares of common stock and 29,608 restricted stock units.
The options vest in three annual installments: 12,278 shares on February 26, 2027, and 12,277 shares on each of February 26, 2028 and February 26, 2029. The restricted stock units vest similarly: 9,870 on February 26, 2027, then 9,869 on each of February 26, 2028 and February 26, 2029. Each restricted stock unit represents a right to receive one share of common stock, and vested units may be settled in stock, cash, or a combination.
INOVIO PHARMACEUTICALS, INC. CFO Peter Kies received equity awards in the form of stock options and restricted stock units on March 4, 2026. He was granted 31,240 common stock options at an exercise price of $0.0000 per share, all held as direct ownership.
The options vest in three installments: 10,414 shares on February 26, 2027, 10,413 shares on February 26, 2028, and 10,413 shares on February 26, 2029. He was also granted 25,520 restricted stock units, each representing a contingent right to receive one share of common stock, with 8,507 units vesting on February 26, 2027, 8,507 on February 26, 2028, and 8,506 on February 26, 2029. Vested restricted stock units can be settled in common stock, cash, or a combination of both.
INOVIO PHARMACEUTICALS, INC. Chief Scientific Officer Laurent Humeau reported several equity award-related transactions on February 26, 2026. He exercised restricted stock units into common stock in multiple tranches, including 5,010 and 7,366 units, each converting into an equal number of common shares at $0.00 per share.
In connection with these vesting and settlement events, the issuer withheld 2,064 and 3,034 common shares at a price of $1.79 per share to cover Mr. Humeau’s tax withholding obligations, as described in the footnotes. These are administrative equity award and tax-withholding transactions rather than open-market purchases or sales.
INOVIO PHARMACEUTICALS, INC. CFO Peter Kies reported equity award activity on February 26, 2026. He acquired 5,010 and 10,634 shares of common stock through the vesting and settlement of previously granted restricted stock units, at a stated price of $0.00 per share.
To cover related tax withholding obligations, the issuer withheld 2,965 and 6,294 shares at $1.79 per share, recorded as tax-withholding dispositions rather than open-market sales. Following these transactions, Kies held common stock directly and also had an indirect holding of 375 shares attributed to his spouse.
INOVIO PHARMACEUTICALS, INC. Chief Executive Officer Jacqueline Elizabeth Shea reported vesting of restricted stock units and related tax share withholdings. On February 26, 2026, 18,632 and 28,401 restricted stock units converted into the same number of common shares, while 8,057 and 13,657 shares were withheld to cover tax obligations.
INOVIO PHARMACEUTICALS, INC. Chief Medical Officer Michael John Sumner reported vesting and settlement of previously granted restricted stock units into common stock. On February 26, 2026 he acquired 5,010 and 11,550 shares of common stock upon exercise or conversion of vested restricted stock units granted in 2024 and 2025, respectively. A total of 3,903 common shares were withheld by the company at a price of $1.79 per share to cover his tax obligations related to this vesting. Following these transactions, Sumner directly owned 30,507 shares of INOVIO common stock.
INOVIO PHARMACEUTICALS director David B. Weiner acquired 972 shares of common stock through an RSU conversion. On February 26, 2026, 972 restricted stock units vested and were exercised at $0.00 per share, converting into 972 common shares.
These units were part of a 2,916‑unit grant made on February 27, 2023, vesting in three equal installments of 972 units on February 26 of 2024, 2025, and 2026. After this transaction, Weiner directly holds 87,592 shares of INOVIO common stock, and no restricted stock units from this grant remain outstanding.